Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cendrine Lemoine

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Medecine Sciences : M/S|January 7, 2020
[Developability assessment with case studies highlighting the decision taking]Jacques Dumas, Anne Sévérac, Cendrine Lemoine, et al.
Oncoimmunology|September 6, 2021
Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatmentHélène Bonnevaux, Stephane Guerif, Jana Albrecht, et al.
Blood|June 10, 2025
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myelomaBenjamin T Diamond, Linda B Baughn, Mansour Poorebrahim, et al.
Nature Cancer|February 5, 2022
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulationLan Wu, Edward Seung, Ling Xu, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Medecine Sciences : M/S|January 7, 2020
[Developability assessment with case studies highlighting the decision taking]Jacques Dumas, Anne Sévérac, Cendrine Lemoine, et al.
Oncoimmunology|September 6, 2021
Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatmentHélène Bonnevaux, Stephane Guerif, Jana Albrecht, et al.
Blood|June 10, 2025
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myelomaBenjamin T Diamond, Linda B Baughn, Mansour Poorebrahim, et al.
Nature Cancer|February 5, 2022
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulationLan Wu, Edward Seung, Ling Xu, et al.
Pageof 1